Status:
COMPLETED
Terlipression Prevent Developing of Acute Kidney Injury During Upper-gastroentestinal Bleeding
Lead Sponsor:
Changhai Hospital
Conditions:
Cirrhosis, Liver
Upper Gastrointestinal Bleeding
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The investigators studied the renal function index level in terlipressin treated cirrhotic patients with upper-gastrointestinal bleeding at different time point.
Detailed Description
54 cirrhotic patients with uppre-gastrointestinal bleeding were entrolled and were distributed into terlipressin group and control group at 1:1 rate. Patients in Terlipressin group received 1mg/6h of ...
Eligibility Criteria
Inclusion
- Diagnosied as cirrhosis with upper gastrointestinal bleeding 18≤age≤70 Varicose vein rupture occurred within 24 hours, Without drug, endoscopy or interventional therapy Can read, understand and sign informed consent
Exclusion
- Pregnant women, lactating women; Serious cardiovascular disease: history of acute cardiac infarction, heart block, heart failure, arterial hypertension(（SBP\>170mmHg and/ or DBP\>100mmHg） Occlusive lower extremity venous disease Asthma, chronic obstructive pulmonary disease Have serious or unable to control other organ diseases; Cerebrovascular disease; Age ≥70 years old Known to be allergic to therapeutic drugs Chronic kidney disease Weight ≤40kg
Key Trial Info
Start Date :
January 1 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2020
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT04358016
Start Date
January 1 2018
End Date
March 1 2020
Last Update
April 22 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Changhai hospital
Shanghai, China, 200433